Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,301–12,400 of 15,747
Jafar, A. J. N., Darbyshire, D., Prager, G., Reynard, C., & Naguib, M. P. (2020) · Emergency Medicine Journal · doi:10.1136/emermed-2020-210979 · Cited by 1
RNA viruses: from RNA processing and interaction mechanisms to new prevention and control strategies
ZHANG, F., Tang, Y., Yu, J. I. A., & Zhou, Y. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0100 · Cited by 1
Pastorio, C., Zech, F., Noettger, S., Jung, C., Jacob, T., Sparrer, K. M. J., & Kirchhoff, F. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4099078 · Cited by 1
Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders
(2021) · doi:10.1101/2021.11.30.21266716 · Cited by 1
“After 2 doses of either BNT162b2 or mRNA1273, antibodies to spike protein and neutralising antibodies have been quantified in vaccine recipients(1,2,10,11).”
Monte, G., Papetti, L., Ferilli, M. A. N., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1106472 · Cited by 1
“Median age at first dose, years (range) 11 (6-15) 16 (10-19) 16 (10-22)”
BackgroundPapa, A., Scaldaferri, F., Vetrone, L. M., Neri, M., Gasbarrini, A., & Lopetuso, L. R. (2021) · Vaccines · doi:10.3390/vaccines9030248 · Cited by 1
Zhai, L., Zhuang, M., Wong, H. K., Lin, C., Ying, H., Zhang, J., Bao, G., Zhang, Y., Xu, S., Luo, J., et al. (2025) · MedComm · doi:10.1002/mco2.70469 · Cited by 1
“Mouse In the first experiment, mice were administered the BioNTech COVID-19 mRNA vaccine by intramuscular injection at a dose of 4.5 µ g/kg once per week for 4 weeks, according to the dosage used in humans [9].”
InfluentialAs COVID-19 cases surge despite mass vaccination, it’s time to focus on the vulnerable
Little, M., Fittall, M. W., McKenzie, H., Tilby, M., Tripathy, A. R., & Lee, L. Y. W. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.ed117 · Cited by 1
“ed117 2 COVID-19 vaccination is clearly effective in the general population, with a wealth of trial evidence and real-world data to support this [4-6].”
BackgroundHuman Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System
Ernzen, K., Trask, A. J., Peeples, M. E., Garg, V., & Zhao, M. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10229-4 · Cited by 3
mRNA vaccines for viral diseases: mechanism, advances, and future perspective
Chakraborty, B., & Singh, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11856-1 · Cited by 2
Elzouki, A.-N. Y., Elshafei, M. N., Aziz, A., Elzouki, I., Waheed, M. A., Farooqui, K., Azad, A. M., Habas, E. M., & Danjuma, M. I.-M. (2023) · Qatar medical journal · doi:10.5339/qmj.2023.21 · Cited by 1
Gupta, D., Ahmed, F., Tandel, D., Parthasarathy, H., Vedagiri, D., Sah, V., Mohan, B. K., Daga, S., Khan, R. A., Kondiparthi, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434030 · Cited by 1
Romain‐Scelle, N., Elias, C., & Vanhems, P. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.036 · Cited by 1
“Clinical studies have now demonstrated the benefit of the vaccines beyond protection against the development of severe cases of COVID-19 with an efficacy between 60% and 85% [1,2], a reduction in viral load among asymptomatic carriers [3,4] and therefore, a reduction in transmissibility [5,6].”
Vaccines and Vaccination Strategies for Older Adults
Weinberger, B. (2021) · Healthy ageing and longevity · doi:10.1007/978-3-030-87532-9_7 · Cited by 1
Atreja, A., Kalra, S., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_47 · Cited by 1
Fousse, M., Klemis, V., Bronder, S., Urschel, R., Hielscher, F., Fassbender, K. C., Sester, U., Sester, M., & Schmidt, T. (2025) · Brain and Behavior · doi:10.1002/brb3.70849 · Cited by 1
“to mitigate the risk of infection and severe disease progression (Polack et al. 2020).”
Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccination
Okumura, N., Saito, S., Takamatsu, Y., Takeuchi, J. S., Asai, Y., Sanada, M., Iwamoto, N., Maeda, K., Mitsuya, H., & Ohmagari, N. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.08.026 · Cited by 1
“However, the efficacy immediately after the first dose of vaccination is reported to be not significantly different from that in the placebo group [1,2].”
BackgroundSARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression
Schirmeister, I., Eckert, N., Weigang, S., Fuchs, J., Kern, L., Kochs, G., & Halenius, A. (2025) · Viruses · doi:10.3390/v17081083 · Cited by 2
“Neutralizing antibodies targeting the spike protein lose efficacy as the virus evolves [4], whereas CD8+ and CD4+ T-cell responses remain relatively conserved and play a crucial role in limiting viral replication and reducing disease severity [5–9].”
Vaccination COVID en pneumologie.
Blanchard, E. J., Ozier, A., Janssen, C., Wyplosz, B., & Andréjak, C. (2021) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2021.07.003 · Cited by 3
Gao, F., Mallajoysula, V., Arunachalam, P. S., Manohar, M., Röltgen, K., Yang, F., Wirz, O. F., Hoh, R. A., Haraguchi, E., Lee, J.-Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4173451 · Cited by 1
De-Leon, H., & Pederiva, F. (2021) · medRxiv · doi:10.1101/2021.08.10.21261856 · Cited by 1
“[5] Fernando P Polack, Stephen J Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John L Perez, Gonzalo Pérez Marc, Edson D Moreira, Cristiano Zerbini, et al.”
BackgroundVaccination strategies against SARS-CoV-2: General impact on the development of the pandemic
de Miguel, Á. G., & Gil-Prieto, R. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/s01.18.2021 · Cited by 1
“Clinical trial results were published in The New England Journal of Medicine (NEJM) at the end of 2020 [4].”
Peptide-Coated Nanoparticles for Noninvasive Biomedical Imaging
Dragulska, S. A., Santiago, M. A., Poursharifi, M., & Mieszawska, A. J. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4402-7_3 · Cited by 2
Gao, R., Zheng, C., Yang, M., Dai, L., Chen, C., Yao, J., Zhang, Z., Tang, L. M., Shi, Y., & Han, X. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2274484 · Cited by 1
“Although the safety and efficacy of the vaccines have been proven [7–9], the data on cancer patients, especially those with active malignancies are limited.”
BackgroundEngineered mRNA Nanoparticle Platforms for Respiratory Mucosal Delivery
Jin, R., Wang, B., & Zhu, W. (2026) · Vaccines · doi:10.3390/vaccines14070596 · Cited by 1
Placental lesions induced by Omicron SARS-CoV-2 in a pregnant woman treated with anti-CD20
Dubucs, C., Dupuis, N., Jourdes, A., Delobel, P., Auzet, C., Acker, N. V., Pasquier, C., & Aziza, J. (2025) · Placenta · doi:10.1016/j.placenta.2025.03.015 · Cited by 2
Blachier, S., Vaney, M. C., Conquet, L., Staropoli, I., Fernández, I., Giraud, É., Arbabian, A., Michel, V., Szilagyi, F., Guez, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65144-w · Cited by 2
Modeling The Impact of Vaccination On COVID-19 And Its Delta VariantPreprint
Wang, J., Chan, Y.-C., Niu, R., Wong, E. W. M., & van Wyk, M. A. (2021) · Research Square · doi:10.21203/rs.3.rs-1171015/v1 · Cited by 1
Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs Against COVID-19
Paschall, A. V., & Avci, F. Y. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162572-00112 · Cited by 1
Kasztelewicz, B., Skrok, K., Burzyńska, J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3255069/v1 · Cited by 1
RNA therapy is shining for genetic diseases
Zheng, Z. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102042 · Cited by 1
Abe, T., Mitsukawa, N., Thiebaud, R. S., & Loenneke, J. P. (2020) · Journal of Trainology · doi:10.17338/trainology.9.2_64 · Cited by 1
Weigl, J. A. I., Werlang, T., Wessendorf, M., & Helbing, H. (2021) · Journal of Public Health · doi:10.1007/s10389-021-01650-7 · Cited by 12
Simulation Insights into the Assembly of Polyplexes for RNA Delivery
Lehnen, J. H., Herrero, J. M., Haas, H., Schmid, F., & Settanni, G. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c01219 · Cited by 2
Delayed-type hypersensitivity reactions to Pfizer BioNTech SARS-CoV-2 vaccine
Beyaz, Ş., Çimşir, D. Ö., Sözener, Z. Ç., et al. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-141420 · Cited by 1
Miyazawa, K., Bazzazi, H., & Gao, W. (2026) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-026-10052-9 · Cited by 2
“This is exemplified by the unprec - edented speed and scale with which mRNA based vaccines were developed against SARS-COV-2 during the COVID-19 pandemic [1, 2].”
Begum, F., Panda, M., & Agarwal, A. (2023) · Indian Journal of Postgraduate Dermatology · doi:10.25259/ijpgd_18_2022 · Cited by 1
Epidemiology Aspects of Magnetic Resonance Imaging in the Context of COVID-19 PandemicPreprint
Сергеевна, М. А., Shelkovnikova, T. A., Игоревна, Р. Н., Витальевна, М. О., Харисович, В. В., Анатольевна, Т. И., Novikova, O. M., Naiman, A. B., Kuznetsova, A. D., Chesalov, N. P., et al. (2023) · Preprints.org · doi:10.20944/preprints202303.0059.v1 · Cited by 1
COVID-19 breakthrough infections and pre-infection neutralizing antibody
(2021) · doi:10.1101/2021.10.20.21265301 · Cited by 1
“4 Introduction Clinical trials show that the mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in lowering the risk of coronavirus disease (COVID-19).(1,2) In countries with high coverage of vaccination programs, however, the number of COVID-19 patients has s…”
BackgroundTrigueros, M., Pradenas, E., Palacín, D., Ávila-Nieto, C., Trinité, B., Bonet-Simó, J. M., Isnard, M., Moreno, N., Marfil, S., Rovirosa, C., et al. (2021) · medRxiv · doi:10.1101/2021.11.18.21266502 · Cited by 2
Direct cytosol delivery of mRNA by micron-sized co-assembly with designer oligopeptides
Feng, R., Rafiei, M., Fernando, K. S., & Chau, Y. (2025) · Journal of Materials Chemistry B · doi:10.1039/d4tb01098a · Cited by 3
Blumenfeld, O., Rosenberg, A., Reuven, M., Caspi, I., Sharoni, E., & Leviner, D. B. (2023) · Infection Prevention in Practice · doi:10.1016/j.infpip.2023.100334 · Cited by 1
COVID-19 vaccines: Facts and controversies
Kaul, D. (2021) · Current Medicine Research and Practice · doi:10.4103/cmrp.cmrp_11_21 · Cited by 2
Iterative Upgrading of mRNA Therapeutics by Modulating the Microenvironment for Translation
Shi, Y., Lou, Z., Wang, Y., Li, M., Wang, Y., & You, J. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202414722 · Cited by 1
Evaluation of Vaccine Strategies among Healthcare Workers during COVID-19 Omicron Outbreak in Taiwan
Lin, M.-R., Huang, C., Chiu, C.-H., & Chen, C. (2024) · Vaccines · doi:10.3390/vaccines12091057 · Cited by 1
“These findings are consistent with earlier reports indicating higher reactogenicity profiles for these vaccine types [4,5].”
ResultSpehner, L., Orillard, É., Falcoz, A., Lepiller, Q., Bouard, A., Almotlak, H., Kim, S. C. H., Curtit, E., Meynard, G., Jary, M., et al. (2023) · BMJ Oncology · doi:10.1136/bmjonc-2023-000054 · Cited by 1
Current Development of Data Resources and Bioinformatics Tools for Anticoronavirus Peptide
Li, B., Li, M., Lu, C., Wu, Y., Chen, H., & He, B. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673264218231121104407 · Cited by 1
Berber, E., Jarrett, E. E., Hanley, H. B., Uno, N., & Ross, T. M. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2547517 · Cited by 2
Noncoding RNAs and the Architecture of Gene Regulation: Focus on Long and Small Regulatory RNAs
Desind, S. Z., Bell, S. K., & Lutz, C. S. (2026) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.70051 · Cited by 2
“…successful clinical trials and regulatory ap-provals over the past decade have demonstrated that RNA drugs can achieve prolonged, sustained treatment effects in humans (Adams et al. 2018; Finkel et al. 2017; Paunovska et al. 2022; Polack et al. 2020; Syed 2025 et al. 2021; NCT06128629 , 2023).”
Statistical Inferences and Analysis based on the COVID-19 Data from the United StatesPreprint
Rethnakar, N. (2021) · medRxiv · doi:10.1101/2021.11.30.21267096 · Cited by 1
Rodríguez, J. L. G., Parrado, C. V., Ramos, J., Bouallou, A., de la Hoz, M. Á. A., & Argüelles‐Arias, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-25370-0 · Cited by 1
Multi-objective computational optimization of human 5′ UTR sequences
Yamada, K., Suga, K., Abe, N., Hashimoto, K., Tsutsumi, S., Inagaki, M., Hashiya, F., Abe, H., & Hamada, M. (2024) · bioRxiv · doi:10.1101/2024.11.12.622374 · Cited by 7
Piovesan, C., Fabiani, M., Pezzotti, P., & Ramigni, M. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108392 · Cited by 1
Warkentin, L., Lippert, N., Kühlein, T., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3949414 · Cited by 1
Smoll, N. R., Walker, J., Imam, M. H. A., Auriac, J., Andrews, R., Jeremijenko, A. M., Kirk, M., & Khandaker, G. (2022) · Communicable Diseases Intelligence · doi:10.33321/cdi.2022.46.40 · Cited by 1
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331654 · Cited by 1
“The introduction of vaccination with COVID-19 mRNA vaccines, namely BNT162b2 (Pfizer-BioNTech) [6] and mRNA-1273 (Moderna) [7], marked a turning point in the pandemic.”
Adverse events following vaccination against coronavirus disease 2019
Jeon, M., Jin, S., & Lee, J. Y. (2022) · Kosin Medical Journal · doi:10.7180/kmj.22.017 · Cited by 1
“A total of 43,548 participants aged 16 years and over were enrolled in a randomized controlled trial to evaluate the safety and efficacy of BNT162b2 [7].”
BackgroundAdverse events after COVID-19 vaccination: Vector- or spike-induced?Preprint
Poulas, K. A. (2021) · doi:10.32388/a9wpxh · Cited by 1
Canetti, M., Barda, N., Gilboa, M., Indenbaum, V., Mandelboim, M., Gonen, T., Asraf, K., Weiss-Ottolenghi, Y., Amit, S., Doolman, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1946528/v1 · Cited by 1
Viral Mitigation: Weak Theoretical Underpinnings
Karadimas, P. (2023) · Studies in Public Choice · doi:10.1007/978-3-031-24967-9_2 · Cited by 1
Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 SpreadPreprint
Kamal, M. A., Kuznik, A., Qi, L., Więcek, W., Hussein, M. A., Hassan, H. E., Patel, K., Obadia, T., Toroghi, M. K., Conrado, D. J., et al. (2021) · medRxiv · doi:10.1101/2021.05.21.21257624 · Cited by 1
Syed, A. S., Sultana, S., Begum, A., Nadeem, K., Ara, J., Askarey, S. H., Siddiqui, A. A., Anwar, A., & Hashmi, A. A. (2023) · Cureus · doi:10.7759/cureus.46682 · Cited by 2
“It is predicted that the efficacy rates are 83.5% and 95% for Sinovac and Pfizer vaccines, respectively [6,7].”
BackgroundInfluentialTanaka, H., Sawatari, H., & Ando, S. (2023) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2023.175 · Cited by 1
COVID ‐19 Vaccine‐Induced Severe Pneumonitis
Suzuki, T., Furuta, H., Naganawa, M., et al. (2025) · Respirology Case Reports · doi:10.1002/rcr2.70274 · Cited by 1
Yu, D., Huang, X., Zang, H., et al. (2023) · ISPRS International Journal of Geo-Information · doi:10.3390/ijgi12020069 · Cited by 1
Mendiboure, V., Teiti, I., Aubry, M., Teissier, A., Paoaafaite, T., Vanhomwegen, J., Manuguerra, J., Fontanet, A. L., Cao‐Lormeau, V., & Madec, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-17869-4 · Cited by 2
“However, those who self-reported having been tested positive for COVID-19 by a health professional, prior to or within the same month as vaccination, were considered as unvaccinated for the analysis to reflect the time required for the vaccine to induce immune protection [15].”
BackgroundResultInfluentialTelemedical management of symptomatic COVID-19 outpatients
von Falkenhausen, A. S., Geipel, S., Gail, A., Scherer, C., Stockhausen, S., Sams, L. E., Becker, F., Doldi, P. M., Lemmermöhle, E., de Villèle, P., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00277-2024 · Cited by 2
“With the advent of vaccines [14 – 16] and therapeutic options [17], combined with less virulent SARS-CoV-2 variants [18, 19], the threat to individual health faded.”
BackgroundScutelnic, A., Brodard, J., Hovinga, J. A. K., et al. (2022) · Clinical and Translational Neuroscience · doi:10.3390/ctn6020011 · Cited by 1
Myocarditis after COVID-19 Vaccination
Hashimoto, N., & Kashio, K. (2023) · Open Journal of Emergency Medicine · doi:10.4236/ojem.2023.111004 · Cited by 1
Kim, J., Kachko, A. V., Selvaraj, P., Rotstein, D. S., Stauft, C. B., Rajasagi, N. K., Zhao, Y., Wang, T. T., & Major, M. E. (2025) · npj Vaccines · doi:10.1038/s41541-025-01085-1 · Cited by 4
Kermer, P., Abdalla, Y., Klein, G., & Lüers, C. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100257 · Cited by 1
“3 % of vaccinees in the Biontech pivotal study [2], but reached more than 5 % in our cohort over both injections.”
Seok, J. M., Na, E. J., Kim, S. G., Park, J., Park, E., Song, P., & Yang, K. I. (2022) · Journal of Sleep Medicine · doi:10.13078/jsm.210022 · Cited by 1
Burden of COVID-19 variant omicron in immunocompromised patients in Spain: Systematic review
Ortiz-de-Lejarazu, R., Gili, B. Q., & García, A. L. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2024.09.001 · Cited by 2
Shamsollahi, H. R., Younesian, S., Nikfarjam, A., Nasiri, Z., & Yunesian, M. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42670 · Cited by 1
“The vaccines have shown varying degrees of effectiveness in preventing infection, hospitalization, severe or critical illness, and death [6,7].”
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question
Triggle, C. R., & MacDonald, R. S. (2025) · Viruses · doi:10.3390/v17070881 · Cited by 2
“The timely availability of the genome sequence for SARS-CoV-2 enabled the fast-tracking of a number of vaccines, including the novel mRNA vaccines developed by Pfizer-BioNTech and Moderna [7,8].”
Altomare, C. G., Adelsberg, D. C., Carreño, J. M., Sapse, I. A., Amanat, F., Ellebedy, A. H., Simon, V. R., Krammer, F., & Bajic, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.08.451649 · Cited by 1
Precautions for breast ultrasound examination following COVID-19 vaccination
Ha, S. M., & Chang, J. M. (2021) · Journal of Korean Medical Association · doi:10.5124/jkma.2021.64.10.671 · Cited by 1
Nanoparticles for Drug Delivery: Design, Mechanisms, and Clinical Translation
Jose, S. A., Crutchfield, B., Caballero, M., Carreon, E., Davis, I., & Menezes, P. L. (2026) · Molecules · doi:10.3390/molecules31173121 · Cited by 1
“Similarly, pivotal Phase III trials of LNP-formulated mRNA COVID-19 vaccines demonstrated 95.0% efficacy for BNT162b2 and 94.1% efficacy for mRNA-1273 against symptomatic COVID-19, providing large-scale clinical validation of LNP-mediated mRNA delivery [62–64].”
InfluentialKim, M. J., Prieto‐Merino, D., Nicholas, J. M., Allen, L. N., Burton, M. J., Bastawrous, A., & Macleod, D. (2025) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.70197 · Cited by 2
López, V., Mazuecos, A., Villanego, F., et al. (2022) · Nefrología · doi:10.1016/j.nefro.2022.11.001 · Cited by 1
Menghini, G. M., Thurnheer, R., Kahlert, C. R., Kohler, P. P., Grässli, F., Stocker, R. A., Battegay, M., & Vuichard‐Gysin, D. (2024) · Swiss Medical Weekly · doi:10.57187/s.3708 · Cited by 1
Lipid-Based Systems for Regenerative Medicine
Patel, P., Bagada, A. A., Garala, K., Singh, S. K., & Prajapati, B. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_5 · Cited by 1
Gawaz, A., Yilmaz, A., Fehrenbacher, B., et al. (2026) · Acta Dermato Venereologica · doi:10.2340/actadv.v106.adv-2025-0308 · Cited by 1
“Possible explanations include delayed degradation of viral proteins after infection (6) or transient expression following mRNA vaccination (7–10).”
Jansen, K. U. (2021) · doi:10.33442/vt202107 · Cited by 1
Self-citationSasaki, J., Sato, A., Sasaki, M., Okabe, I., Kodama, K., Otsuguro, S., Yasuda, K., Kojima, H., Orba, Y., Sawa, H., et al. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.106039 · Cited by 1
Hironori Nakagami, A., Hayashi, H., Ishihama, T., et al. (2021) · Translational and Regulatory Sciences · doi:10.33611/trs.2021-016 · Cited by 1
Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients
Korouri, E., Jeong, C. Y., Peterson, H., Valenzuela, F., Romiti, R., Didaskalu, J. A., Egeberg, A., Oon, H. H. B., Maul, L. V., Kingston, P., et al. (2024) · Life · doi:10.3390/life14101297 · Cited by 2
Decoding the Functional Roles of Individual Components in mRNA Lipid Nanoparticles
Su, K., Wang, Z., Shi, L., Fu, X., Sheng, X., Kong, N., Xu, T., & Liu, S. (2026) · ACS Nano · doi:10.1021/acsnano.6c07039 · Cited by 3
Inizan, C., Courtot, A., Sturmach, C., Griffon, A.-F., Biron, A., Bruel, T., Enouf, V., Demaneuf, T., Munier, S., Schwartz, O., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004397 · Cited by 2
Engindeniz, Z., ENGİNDENİZ, F. T., & Özdemir, A. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089069 · Cited by 1
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.